Orphan designation: 4-[[(4-Methoxyphenyl)thio]methyl]-N,N-dimethyl-1H-1,2,3-triazole-1-ethanamine Treatment of non-syndromic inherited retinal dystrophies with a rod-dominant phenotype, 11/11/2024 Positive

Orphan designation: 4-[[(4-Methoxyphenyl)thio]methyl]-N,N-dimethyl-1H-1,2,3-triazole-1-ethanamine Treatment of non-syndromic inherited retinal dystrophies with a rod-dominant phenotype, 11/11/2024 Positive

Orphan designation: 3-chloro-4-fluorophenyl-(4-fluoro-4-(((5-methylpyrimidin-2-ylmethyl)amino)methyl)piperidin-1yl)methanone Treatment of fragile X syndrome, 11/11/2024 Positive

Orphan designation: 3-chloro-4-fluorophenyl-(4-fluoro-4-(((5-methylpyrimidin-2-ylmethyl)amino)methyl)piperidin-1yl)methanone Treatment of fragile X syndrome, 11/11/2024 Positive

Opinion/decision on a Paediatric investigation plan (PIP): Kyprolis, carfilzomib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Haematology-Hemostaseology;Oncology, PIP number: P/0408/2023

Opinion/decision on a Paediatric investigation plan (PIP): Kyprolis, carfilzomib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Haematology-Hemostaseology;Oncology, PIP number: P/0408/2023

Newsletters

Stay informed on our latest news!

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

randomness